explore -WSS

explore

author：fashion 2025-08-23 10:41:14 - browse：1741

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Ultragenyx gene therapy for rare liver ailment succeeds in late

focus

WSS

The 10 drugs up first for Medicare price negotiation

The Pandemic Treaty must support building strong health systems

NIH nominee Bertagnolli will get October confirmation hearing

'Make People Better': The CRISPR babies story you probably don't know

A rare thyroid diagnosis led to unexpected, all

How to protect patients from sexual assault

hotspot

explore

focus

Anesthesiologist group: stop taking Ozempic before surgery

ALS advocates say criticism of new drugs misses bigger picture

Affirmative action in medical school literally saved lives

FDA's Pazdur wants cancer trials to range beyond China alone

Jerome Adams on the need for new antivirals for Covid

Weighted lottery helped low

Medical leaders decry Supreme Court decision on affirmative action

HIV drugs protect against transmission, even in unprotected sex

As demand for Covid shots wanes, Moderna seeks its next success

FDA's Pazdur wants cancer trials to range beyond China alone

focus

Medicaid rebukes states for mistakenly disenrolling children

Advances in CAR

Stem cell treatment guidelines are released by FDA

How to protect patients from sexual assault

House transparency, PBM reform bill gains bipartisan support

Let's speed up science by embracing open access publishing

Wikipedia

entertainment

focus

focus